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Reperfusion therapy has become a practical and effective strategy in the salvage of ischemic
myocardium. The direct enhancement of cardiac cellular tolerance against ischemic and
reperfusion injury should further improve patient outcome in acute coronary syndromes
(ACS). This approach has been explored for many decades, and although we await
mortality-weighted randomized clinical trials, the infusion of glucose-insulin-potassium
(GIK) has shown promise in protecting post-infarct myocardium. The current dogma is that
this cardioprotective effect of GIK acts via the modulation of cardiac and circulating
metabolites to provide the heart with an optimal metabolic milieu to resist ischemia and
reperfusion injury. This concept of metabolic modulation has gained favor in coronary heart
disease, and its efficacy currently is being investigated in stable angina using the new class of
partial fatty acid oxidation inhibitors, including trimetazidine and ranolazine. We contend
that the mitogen insulin, itself, promotes tolerance against ischemic cell death via the
activation of innate cell-survival pathways in the heart. To advance this viewpoint, we will
present clinical data that support a dose-dependent effect of insulin’s beneficial action in the
management of acute myocardial infarction. Furthermore, we present experimental data that
identify cell-survival programs that are directly activated by the administration of insulin.
Finally, as intravenous insulin therapy is both labor intensive and associated with metabolic
perturbations, we propose that the development of pharmaco-therapeutic agents that target
downstream cell-survival insulin-activated signaling molecules may be an alternate approach
to promote cardioprotection during ACS. (J Am Coll Cardiol 2003;41:1404–7) © 2003 by
the American College of Cardiology Foundation
The concept that the metabolic cocktail, glucose-insulin-
potassium (GIK), may protect ischemic cardiomyocytes was
initially introduced by Sodi-Pallares in 1962 (1). The
further rationale for the use of this metabolic therapy was
proposed by Opie (2) in 1970, when he suggested two chief
mechanisms: the promotion of cardiac glycolysis and the
diversion of free fatty acids (FFA) to adipocytes, with a
resultant reduction in cardiac FFA metabolism. A number
of early clinical studies with administration of this metabolic
cocktail yielded promising results, and a subsequent meta-
analysis suggested that GIK therapy might have an impor-
tant role in reducing in-hospital mortality after acute myo-
cardial infarction (AMI) (3). In the “myocardial reperfusion
era” the randomized controlled Estudios Cardiologicos
Latinoamerica (ECLA) study suggested that patients who
underwent reperfusion therapy had reduced in-hospital
mortality after the co-administration of GIK (4). Accep-
tance of the benefits and the subsequent use of this
metabolic cocktail have, however, not been forthcoming,
despite almost four decades having passed since such ther-
apy was proposed. The reason for the lack of enthusiasm is
multi-factorial and includes the lack of large clinical studies,
the poor understanding of the basic mechanisms of how this
metabolic cocktail acts, and the complexity in administering
this therapeutic cocktail. To adequately address the efficacy
of GIK, a large randomized clinical study is now underway
(GIK II: http://www.ecla.org.ar). Furthermore, alternate
therapeutic strategies to optimize glucose utilization in the
management of stable coronary artery disease are being
explored (5–7). The most promising appear to be via the
promotion of glucose oxidation using the partial fatty acid
oxidation (pFOX) inhibitors in the context of stable angina
(8,9). However, in our opinion, the use of these alternate
“metabolic-modulatory” strategies does not incorporate the
putative direct beneficial effects of insulin administration
during acute coronary syndromes (ACS). In this regard,
research from our laboratories and other laboratories impli-
cates the direct cell survival effects of insulin as a “metabol-
ically independent” component of the GIK cocktail (10–
12). The clinical data and a proposed insulin-directed cell
survival hypothesis conferring these cardioprotective effects
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are discussed. Finally, pharmacologic targeting of insulin
signaling may be appropriate in future drug development to
promote this cardiac tolerant state in the context of ACS.
The clinical case for GIK in cardioprotection. The meta-
analysis of 1,932 patients randomized to GIK therapy or
placebo in the “pre-reperfusion era” demonstrated that GIK
therapy could save an additional 49 lives per 1,000 patients
treated for AMI (3). Although studies need to be per-
formed, it was assumed that the benefit of this therapy
might be less applicable in the current aggressive thrombol-
ysis and acute revascularization era. However, as was shown
in the ECLA study, a statistically significant reduction in
mortality after AMI was obtained in patients who received
concomitant reperfusion treatment with the GIK cocktail
(4). It is interesting that, in the one-year follow-up data
from the ECLA study, only those subjects who had received
the high-dose GIK therapy had a statistical survival advan-
tage over the control group (4). The decision to use a
high-dose GIK regimen was based on the pioneering
dose-response studies of Rackley and co-workers, who
determined the GIK infusion rates that would result in the
maximal suppression of FFA levels as well as the maximal
myocardial glucose uptake (13). Two additional clinical
studies have been performed in the reperfusion era. The
first, the Diabetes Mellitus, Insulin Glucose infusion in
Acute Myocardial Infarction (DIGAMI) study, was de-
signed to assess the efficacy of glucose and insulin therapy in
diabetic patients who presented with AMI (14). Long-term
subcutaneous insulin therapy was instituted beyond the
acute-infarction period in the non-insulin-dependent dia-
betic patients (who constituted approximately 80% of the
subjects in the DIGAMI study). Despite these differences,
the end result was similar to a 29% relative risk reduction for
mortality in the patients treated with insulin and glucose. In
the second study, Ceremuzynski et al. (15) did not show any
beneficial effect of low-dose GIK therapy. Apstein and Opie
(16) reviewed the different GIK doses in the ECLA and the
Ceremuzynski studies and suggested that the higher insulin
dosing in the ECLA study was consistent with the previous
pre–reperfusion era studies that showed a benefit of high-
dose GIK therapy (reviewed [17]). Collectively, these clin-
ical studies support a role for GIK therapy after an AMI and
suggest that the dose of insulin needs to be optimal to confer
this benefit. This latter finding supports the metabolic
optimization hypothesis as a mechanism underlying the
mortality-reducing effects of GIK (13,14). In support of the
metabolic hypothesis, clinical studies have demonstrated an
anti-anginal effect of newer metabolic modulators in pa-
tients with stable angina (6,8,9).
Experimental data to support a direct cardioprotective
effect of insulin. After the ECLA clinical study, Jonassen
and co-workers (18), in an experimental study, compared
the temporal effects of administering GIK in an in vivo rat
model of myocardial infarction (MI). It is interesting that
GIK was demonstrated here to be equally effective in
reducing the final infarct size, whether administered during
the entire ischemia/reperfusion period or only during the
reperfusion period. Moreover, when GIK was administered
at reperfusion, the early reperfusion FFA and glucose levels
were unchanged compared with those in vehicle-treated
controls. This was significantly different from the FFA and
glucose levels in the animals treated with GIK throughout
the ischemia/reperfusion period (18). To further delineate
this observation and to establish the role of insulin at
reperfusion, we used the isolated perfused rat heart model of
ischemia and reperfusion. Here, insulin was administered
alone at reperfusion and demonstrated that an immediate
15-min treatment with insulin resulted in the same reduc-
tion in infarct size as insulin administered for a 2-h period
after reperfusion (11). Taken together, these data bring into
question the exclusivity of the glucose/FFA hypothesis
concerning the GIK combination’s cardioprotective effects
and implicate an independent cardioprotective effect of
insulin, in its own right, during reperfusion.
Although reperfusion is a prerequisite for tissue salvage
after an MI, there is a price to pay in terms of distinct
reperfusion-associated pathologies (reviewed [19]). One
postulated aspect of this pathology is the development of
reperfusion-induced myocyte loss beyond that sustained as a
consequence of ischemia alone. In this regard, it has recently
been suggested that, in addition to necrosis, a component of
cell death not previously considered in reperfusion injury—
programmed cell death, or apoptosis—may play a biologi-
cally significant role (20). Under experimental conditions,
an increase in apoptosis has been observed in cardiac
reperfusion models, suggesting that the deleterious effects of
reperfusion are, at least in part, due to apoptosis (21–23).
Taking these data into consideration, we have suggested
that insulin may attenuate apoptosis during reperfusion and
hence result in cardioprotection (20). We and others have
shown that insulin can indeed attenuate such apoptotic
processes in a number of tissues (10,12,24).
Because we have demonstrated that insulin appears to
have a direct effect on limiting tissue injury during post-
ischemic reperfusion, our laboratories have focused on
delineating the molecular cell-survival signaling pathways
downstream of insulin that could be orchestrating this
tolerant phenotype in the heart (schematized in Fig. 1).
Initial experiments in cardiomyocytes demonstrated that the
administration of insulin at the moment of reoxygenation
significantly enhanced myocardial cell viability and reduced
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the degree of apoptosis compared with vehicle-alone treated
control cardiomyocytes (10). As insulin is thought to confer
anti-apoptotic effects via the activation of the cell survival
pathways shown in Figure 1, we initially used pharmaco-
logic inhibitors of these signaling transduction pathways
and demonstrated that tyrosine kinase, PI3 kinase, and
p70S6 kinase (S6K) signaling were required for this cardio-
protective phenotype to be functional (10,11). In conjunc-
tion, the activity of the cell-survival promoting signaling
intermediates (i.e., protein kinase B [Akt] and S6K) was
induced by the administration of insulin at reperfusion (11).
Additionally, we demonstrated that insulin therapy at reper-
fusion maintained the pro-apoptotic peptide BAD (Bcl-2/
Bcl-XL-agonist causing cell death) in an inactive phosphor-
ylated form (11). A recent in vivo study confirmed the
anti-apoptotic role of insulin administration at cardiac
reperfusion in the rat (12). Here, Gao et al. (12) identified
an additional signaling cascade (i.e., endothelial nitric oxide
synthase phosphorylation) as a target of insulin activated
PI3-kinase and Akt cardioprotective signaling. Collectively,
these data support a role for insulin in promoting cell
survival at reperfusion putatively via multiple pro-survival
and anti-apoptotic signaling events. As shown in Figure 1,
current knowledge would support a role of Akt activation in
both direct cell survival and glucose metabolism. In contrast,
the S6K is implicated in directly promoting cell survival (25)
and in inhibiting BAD, which when activated, is known to
destabilize mitochondrial membrane integrity and promote
apoptosis (26). We postulate that these insulin-modulated
signaling molecules may be feasible therapeutic targets for
enhancing cardiac tolerance to ischemia in the management
of ACS. Recently, experimental data clearly support a role
for Akt activation in the attenuation of myocardial ischemic
injury (12,27,28). In this context, it has also been shown
that the HMG-CoA reductase inhibitors can also activate
this intracellular kinase to the benefit of the cell (29–31).
Hence, Akt activation may be a reasonable therapeutic
target for the design of future agents to protect the myo-
cardium against the consequences of reperfusion-induced
injury.
Conclusions. For a number of years clinical data have
supported a role of GIK in reducing morbidity and mortal-
ity after MI. The encouraging data from the ECLA and the
DIGAMI studies suggest that this cardioprotective effect
may be achieved over and above benefits obtained with
reperfusion therapy alone. Moreover, the recent experimen-
tal data with the administration of insulin at reperfusion
suggest that the glucose/fatty acid hypothesis may be
incomplete and that insulin may exert direct cardiac cell
survival effects in the context of ischemia and reperfusion
injury. Here, the downstream Akt and S6K signaling
intermediates in the insulin pathway may be novel targets to
manipulate and promote cardiomyocyte salvage in the
management of AMI. An additional possible mechanism of
insulin-activated cardioprotection that has not been dis-
cussed in this viewpoint is its nitric oxide–mediated vaso-
dilatory effects (32). Finally, we hope that the enhanced
understanding of how insulin may directly affect heart
muscle tolerance to ischemia will support the recruitment of
patients into the mortality-weighted ECLA-GIK II study,
the results of which may be of benefit in the future
management of AMI.
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